{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:55:05Z","timestamp":1793656505614,"version":"4.5.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012036","name":"Public Interest Incorporated Foundation Lotte Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012036","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K19198"],"award-info":[{"award-number":["24K19198"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jcyt.2025.06.002","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T11:17:17Z","timestamp":1749208637000},"page":"1173-1178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Yield-driven approach optimizes apheresis of CD19 chimeric antigen receptor-T cell therapy for patients with lymphoma"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9381-0421","authenticated-orcid":false,"given":"Tomoyasu","family":"Jo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6373-3442","authenticated-orcid":false,"given":"Toshio","family":"Kitawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisaki","family":"Mizumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6704-3633","authenticated-orcid":false,"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4171-2162","authenticated-orcid":false,"given":"Momoko","family":"Nishikori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouhei","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8886-6145","authenticated-orcid":false,"given":"Miki","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7678-4284","authenticated-orcid":false,"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9662-5093","authenticated-orcid":false,"given":"Yasuyuki","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2025.06.002_bib0001","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2025.06.002_bib0002","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcyt.2025.06.002_bib0003","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.06.002_bib0004","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/jca.21871","article-title":"Implications of CAR-T cell therapy on apheresis services: a Scottish perspective","volume":"36","author":"Horne","year":"2021","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jcyt.2025.06.002_bib0005","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.bbmt.2018.02.018","article-title":"Building a CAR garage: preparing for the delivery of commercial CAR T cell products at memorial Sloan Kettering cancer center","volume":"24","author":"Perica","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.06.002_bib0006","doi-asserted-by":"crossref","first-page":"365.e361","DOI":"10.1016\/j.jtct.2022.04.013","article-title":"A clinically applicable prediction model to improve T cell collection in chimeric antigen receptor T cell therapy","volume":"28","author":"Jo","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2025.06.002_bib0007","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jcyt.2024.04.001","article-title":"Handling the different requirements for commercial and investigational MNC collections by apheresis","volume":"26","author":"Bobr","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.06.002_bib0008","first-page":"224","article-title":"Prediction of blood volume in normal human adults","volume":"51","author":"Nadler","year":"1962","journal-title":"Surgery"},{"key":"10.1016\/j.jcyt.2025.06.002_bib0009","doi-asserted-by":"crossref","first-page":"102769","DOI":"10.1016\/j.transci.2020.102769","article-title":"Feasibility of leukapheresis for CAR T-cell production in heavily pre-treated pediatric patients","volume":"59","author":"Hutt","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jcyt.2025.06.002_bib0010","doi-asserted-by":"crossref","first-page":"14952","DOI":"10.1038\/s41598-023-42159-1","article-title":"Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy","volume":"13","author":"Jo","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcyt.2025.06.002_bib0011","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/jca.21812","article-title":"Unstimulated apheresis for chimeric antigen receptor manufacturing in pediatric\/adolescent acute lymphoblastic leukemia patients","volume":"35","author":"Jarisch","year":"2020","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jcyt.2025.06.002_bib0012","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.omtm.2019.11.018","article-title":"Optimizing CAR-T cell manufacturing processes during pivotal clinical trials","volume":"16","author":"Tyagarajan","year":"2020","journal-title":"Mol Ther Methods Clin Dev"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532492500739X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532492500739X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:01:47Z","timestamp":1778943707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S146532492500739X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":12,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S146532492500739X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.06.002","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Yield-driven approach optimizes apheresis of CD19 chimeric antigen receptor-T cell therapy for patients with lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}